Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Skin biopsy specimens of three lesions on her back were consistent with cutaneous T-cell lymphoma (CTCL). On physical examination, she had erythematous patches and plaques with ill-defined borders ...

High-potency Class I to II topicals are frequently used first line to suppress inflammation and symptoms of itching. These agents are often useful as therapy for stage IA disease, but are often ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interim Data from IIS Study Shows 75% Response Rate and Three ...

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

"Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial" was originally created and published by ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active ...